ArticleAdvanced healthcare materials2026
Amine-Functionalized Chitosan/dECM Composite Promotes Cutaneous Regeneration and Hair Follicle Activation by Regulating Oxidative Stress and Inflammation.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Ferroptosis-induced immune modulation: a new frontier in glioblastoma therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Hair loss associated with inflammatory scalp conditions is a growing clinical challenge. However, current FDA-approved treatments primarily stimulate hair growth without targeting the underlying oxidative stress or immune-related damage. In this study, we developed a topical, bioactive composite composed of amine-activated carboxymethyl chitosan (aaCMC) and hydrolyzed decellularized extracellular matrix (h-dECM), formulated using a dual supercritical fluid system to ensure solubility and enhance skin penetration. The resulting formulation exhibited antioxidant activity, immunomodulatory effects, and promoted extracellular matrix (ECM) remodeling in vitro. Specifically, the aaCMC + h-dECM composite reduced intracellular reactive oxygen species (ROS) levels and suppressed p38 phosphorylation in human dermal papilla cells, indicating the inhibition of senescence-related pathways. It also attenuated pro-inflammatory cytokine secretion in activated human peripheral blood mononuclear cells and significantly upregulated collagen and fibronectin expression in human dermal fibroblasts. In vivo, the composite accelerated epidermal repair and hair follicle regeneration in a UVB-induced scalp injury mouse model, demonstrating superior regenerative outcomes compared with minoxidil. These results suggest that aaCMC + h-dECM is a multi-functional regenerative platform capable of restoring scalp homeostasis through the combination of ROS modulation, immune regulation, and ECM support. This strategy may provide a multi-functional therapeutic alternative to conventional monotherapies for inflammatory hair loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.